4D Molecular Therapeutics, Inc. Common Stock (NASDAQ: FDMT) last traded at $15.83, down 1.68% on the session. The quote above updates while this page is open; the figures below are drawn from 4D Molecular Therapeutics, Inc. Common Stock’s own filings and are restated only when a new one is published.
4D Molecular Therapeutics, Inc. Common Stock trades on NASDAQ under the ticker FDMT. Its market capitalisation is $874.04 million.
Valuation measures for 4D Molecular Therapeutics, Inc. Common Stock, derived from the latest quote and its most recent SEC filing.
| Market cap | $874.04M |
|---|---|
| Enterprise value | $888.62M |
| Price / sales | 9.50 |
| Price / book | 2.14 |
| Beta | 1.94 |
Trailing-twelve-month figures tagged in 4D Molecular Therapeutics, Inc. Common Stock's XBRL filings with the SEC.
| Revenue (TTM) | $92.01M |
|---|---|
| Net income (TTM) | -$179.18M |
| EPS (TTM) | -$2.63 |
| Operating margin | -214.24% |
| Return on equity | -43.95% |
| Cash | $70.37M |
Range and volume for FDMT over the past 52 weeks.
| 52-week high | $16.93 |
|---|---|
| 52-week low | $5.97 |
| Volume | 907.6K |
| Average volume | 950.0K |
| Previous close | $16.10 |
A dash means FurlPay does not have that figure, not that it is zero. Nothing on this page is investment advice or a recommendation to buy or sell any security. Figures are provided for information only and may be delayed or restated.